Sight Sciences, Inc. (Nasdaq: SGHT), headquartered in Menlo Park, California, announced today the publication of results in the American Journal of Ophthalmology (AJO) International. These results stem from a large-scale, real-world clinical outcomes study comparing patients treated with three leading minimally invasive glaucoma surgery (MIGS) technologies.
The study, conducted using the American Academy of Ophthalmology IRIS® Registry, analyzed the long-term 2-year post-surgical outcomes of patients with primary open-angle glaucoma (POAG). The focus was on patients treated with three FDA-approved/cleared ab interno MIGS devices in the U.S.: OMNI Surgical System (“OMNI”), Hydrus® Microstent, and iStent inject®, both in combination with cataract surgery and as standalone cataract surgery.
OMNI, known for its implant-free, ab interno procedure targeting resistance areas in the conventional outflow pathway, showed promising results. The study evaluated 77,391 patients with glaucoma and 109,745 glaucomatous eyes. Among them, 6,632 patients and 9,000 eyes received MIGS combined with cataract surgery.
The study’s baseline characteristics revealed generally similar intraocular pressure (IOP) and mean number of IOP-lowering medications across the four cohorts. Patients were categorized based on baseline pre-surgical IOP levels (>18 mmHg and ≤18 mmHg), with treatment goals tailored accordingly.
Paul Badawi, co-founder and CEO of Sight Sciences, emphasized the significance of the study’s findings. He highlighted the efficacy of the OMNI procedure in delivering substantial reductions in both intraocular pressure and medication use over two years. Badawi expressed gratitude to Verana Health and the American Academy of Ophthalmology for facilitating access to real-world clinical outcome data.
The study’s authors and affiliations include Michael Mbagwu from Stanford University School of Medicine, Richard Chapman from Verana Health, and other esteemed professionals from various institutions.
The publication reference for the paper is as follows: Michael Mbagwu, Richard Chapman, Kristian Garcia, Cristina Masseria, Jaime E Dickerson, Louis B Cantor, Ab Interno Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery and Cataract Surgery Alone: IRIS® Registry Study, AJO International, 2024,100015, ISSN 2950-2535.
Sight Sciences is dedicated to developing and commercializing innovative eyecare solutions aimed at transforming patient care and improving lives. The company’s OMNI® Surgical System, an implant-free glaucoma surgery technology, is indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Additionally, the TearCare® System technology addresses evaporative dry eye disease due to meibomian gland dysfunction, while the SION® Surgical Instrument aids in ophthalmic surgical procedures.
